|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||7.35 - 7.73|
|52 Week Range||7.22 - 48.64|
|Beta (5Y Monthly)||0.60|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Patient deaths, testing concerns and “weak arguments.” Those are just a few of the issues the FDA had with Sarepta Therapeutics’s recent drug application, according to new documents released this week.
Wave Life Sciences took its first steps this week after a major corporate setback, releasing early data on one of the two potential treatments for Huntington’s disease, which it's developing with Takeda Pharmaceutical Co. Ltd. The drugs are now Wave’s most advanced products in development following its decision earlier this month to halt testing on its Duchenne muscular dystrophy treatment. In an interview with the Business Journal following the news, Wave's CEO stood by the decision to start small.
Wave Life Sciences stock collapsed Monday after the biotech company's experimental Huntington's disease treatment underperformed a rival drug from Roche and Ionis Pharmaceuticals.
The drug was safe and well-tolerated but showed no difference in total huntingtin protein compared with placebo.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Wave Life Sciences stock crashed Monday after the biotech company scrapped development of two Duchenne muscular dystrophy treatments. The decision will benefit rival Sarepta Therapeutics.
Shortly after a competitor announced a victory against the rare disease Duchenne muscular dystrophy, Cambridge biotech Wave Life Sciences announced a defeat.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
Over the last month the Wave Life Sciences Ltd. (NASDAQ:WVE) has been much stronger than before, rebounding by 42...
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -6.47% and -53.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 20% in 2019 (through September 30th). Conversely, hedge […]
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -16.19% and -51.61%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Sarepta's (SRPT) shares surge after safety issues are observed in Pfizer's early-stage clinical study related to its gene therapy for DMD.
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -14.29% and -68.69%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?